Logo

Rosanne Coppola, Bruce Koepfgen

May 13, 2005
Premium

Fisher Scientific said this week that it has named Rosanne Coppola and Bruce Koepfgen to the company's board of directors.

Coppola is currently director of M&F Worldwide, and has held several senior management positions at Citicorp, said Fisher Scientific.

Koepfgen is CEO of Oppenheimer Capital. Prior to this, he was president of management consulting firm Koepfgen Company. He also spent 23 years at Salomon Brothers in various executive positions including managing director.

Filed under

Gene Editing, Gene Silencing, & CRISPR
RNAi
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.